PerkinElmer Inc. (NYSE:PKI) has acquired VisEn Medical Inc., an in vivo molecular imaging technology company based in Bedford, Mass of an undisclosed amount of money.
The Waltham Mass.-based diagnostics maker said it bought VisEn to offer more preclinical research tools to academic institutions and pharmaceutical companies.
VisEn’s fluorescence molecular imaging systems are used for research on cancer, inflammation, cardiovascular, skeletal and pulmonary diseases, the PerkinElmer said.
In April, PerkinElmer company acquired Spokane, Wash.-based Signature Genomic Laboratories LLC, which performs several types of screening for pre-natal and post-natal genetic diseases, as well as cytogenetic testing of chromosome abnormalities.
PerkinElmer will release its 2010 second quarter results on Thursday, the company more than doubled its net income in Q1. Last week, PerkinElmer’s board announced a quarterly dividend of 7 cents per share.
